首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1122409

抗生素市场：按药物类别、分销渠道和地区 - 规模、份额、前景和机会分析，2022-2030

Antibacterial Drugs Market, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年08月16日 | 出版商:

Coherent Market Insights | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

简介目录

抗菌剂来源于细菌和真菌。这些抗菌剂由简单的分子合成，形成复杂的分子。抗生素通过抑制细胞壁形成、增加细胞膜通透性、抑制细胞壁形成、核酸代谢等代谢过程等多种方式来抑制蛋白质合成、核酸代谢等代谢过程。抗生素可以通过增加或减少其代谢来增加或减少其他药物的血清浓度。临床上最相关的相互作用涉及治疗率低的药物。其他药物也可能提高或降低抗生素水平。抗生素包括苯氧甲基青霉素、青霉素 V 和其他用于治疗由细菌引起的疾病的强效药物。抗生素不能治愈病毒感染，例如感冒、流感和大多数咳嗽。

市场动态

预计市场参与者之间的合作伙伴关係等无机活动的增加将在预测期内推动全球抗菌药物市场的增长。例如，2021 年 3 月，Cipla Limited 的附属公司 Cipla USA Inc. 的子公司 Cipla Therapeutics 和专注于健康安全市场的商业阶段製药公司 SIGA Technologies, Inc. 宣布，他们将，除其他外，TB. 宣布了战略合作伙伴关係，以提供持续创新和获得针对生物威胁的新型抗菌剂。

此外，专业製药公司 R-Pharm Group 于 2017 年 4 月与日本综合贸易公司 Mitsui & Co., Ltd. 建立战略合作伙伴关係，后者收购了 R-Pharm Group 约 10% 的股份。宣布已经结束。这一合作伙伴关係将使 R-Pharm 集团能够扩大其在日本的业务存在。

本研究的主要特点

本报告对全球抗菌药物市场进行了详细分析，以 2021 年为基准年，预测了预测期（2022-2030 年）的市场规模（百万美元）和復合年增长率（CAGR%）。 .
解释不同细分市场的潜在收入机会，并描述该市场具有吸引力的投资建议矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
根据公司亮点、产品组合、关键亮点、业绩和战略等参数，展示了全球抗菌药物市场主要参与者的概况。
本研究涵盖的主要公司包括 Spero Therapeutics, Allecra Therapeutics, R-Pharm Group, Melinta Therapeutics LLC, MicuRx, TenNor Therapeutics Ltd, Venatorx Pharmaceuticals, Inc., GlaxoSmithKline plc., AstraZeneca , Bayer AG , Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co., Inc., Eli Lilly and Company, AbbVie Inc., Novartis AG, Pfizer Inc., 和 Sanofi
本报告中的见解将使企业营销人员和高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
The Global Antibacterial Drugs Market 报告针对行业中的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和财务分析师。
利益相关者可以通过用于分析全球抗菌药物市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

调查目的
先决条件
缩写说明

第二章市场展望

举报内容
- 市场定义和范围
执行摘要
- 市场快照：按药物类别
- 市场快照：按分销渠道
- 市场概况：按地区划分
连贯的机会图 (COM)

第 3 章市场动态、法规和趋势分析

市场动态
- 驱动程序
- 限制因素
- 商机
影响分析
主要发展状况
行业趋势
监管场景
最近的产品批准/发布
PEST 分析
搬运工分析

第 4 章全球抗生素市场 - 冠状病毒 (COVID-19) 大流行的影响

对需求的影响
对医疗保健的影响
流行病学

第 5 章全球抗生素市场，按药物类别，2017-2030 年

B-内□胺系统
奎诺酮类
大环内酯类
四环素类
氨基糖甘类
磺胺类系统
苯酚
其他

第 6 章。2017-2030 年全球抗菌药物市场，按分销渠道分列

医院药房
零售药房
在线药店

第 7 章。2017-2030 年按地区分列的全球抗菌药物市场

北美
美国
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地区
欧洲
德国
英国
法国
意大利
西班牙
俄罗斯
其他欧洲地区
亚太地区
中国
印度
日本
澳大利亚
韩国
东盟
其他亚太地区
中东
海合会
以色列
其他中东
非洲
南非
中非
北非

第 8 章竞争格局

热图分析
市场份额分析
- Spero Therapeutics
- Allecra Therapeutics
- R-Pharm Group
- Melinta Therapeutics LLC
- MicuRx
- TenNor Therapeutics Ltd
- Venatorx Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- AstraZeneca
- Bayer AG
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Eli Lilly and Company
- AbbVie Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi

第九章章节

调查方法介绍
关于出版商

简介目录

Product Code: CMI177

Antibacterial drugs are derived from bacteria or molds. These antibacterial drugs are synthesized from simple molecules to form complex molecules. Antibiotics work in a variety of ways, such as inhibiting cell wall production, increasing cell membrane permeability, and interfering with protein synthesis, nucleic acid metabolism, and other metabolic processes by inhibiting cell wall production, nucleic acid metabolism, and other metabolic processes. Antibiotics can raise or lower the serum levels of other medications by increasing or decreasing their metabolism. The most clinically important interactions involve drugs with a low therapeutic ratio. Other drugs can also increase or decrease levels of antibiotics. Antibacterial drugs include a range of powerful drugs such as phenoxymethylpenicillin, penicillin V. and are used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs.

Market Dynamics

Increasing inorganic activities such as partnerships among market players is expected to drive the global antibacterial drugs market growth over the forecast period. For instance, In March 2021, Cipla Therapeutics, a division of Cipla USA Inc., an affiliate of Cipla Limited, and SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on health security market announced a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against bio threats such as tuberculosis and others.

Furthermore, In April 2017, R-Pharm Group, a specialty pharmaceutical company had announced that it entered into a strategic partnership with Mitsui & Co., Ltd., a Japan-based general trading company which acquired around 10% of R-Pharm Group's shares. This partnership would help R-Pharm Group expand its business presence in Japan

Key features of the study:

This report provides an in-depth analysis of the Global Antibacterial Drugs Market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antibacterial drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Spero Therapeutics, Allecra Therapeutics, R-Pharm Group, Melinta Therapeutics LLC, MicuRx, TenNor Therapeutics Ltd, Venatorx Pharmaceuticals, Inc., GlaxoSmithKline plc., AstraZeneca , Bayer AG , Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co., Inc., Eli Lilly and Company, AbbVie Inc., Novartis AG, Pfizer Inc., and Sanofi
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Global Antibacterial Drugs Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the Global Antibacterial Drugs Market

Detailed Segmentation:

Global Antibacterial Drugs Market, by Drug Class:
- B-lactams
- Quinolones
- Macrolides
- Tetracyclines
- Aminoglycosides
- Sulfonamides
- Phenicols
- Others
Global Antibacterial Drugs Market, by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Antibacterial Drugs Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Spero Therapeutics *
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Allecra Therapeutics
- R-Pharm Group
- Melinta Therapeutics LLC
- MicuRx,
- TenNor Therapeutics Ltd
- Venatorx Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- AstraZeneca
- Bayer AG
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Eli Lilly and Company
- AbbVie Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Key Developments
Industry Trends
Regulatory Scenario
Recent Product Approval/Launches
PEST Analysis
Porter's Analysis

4. Global Antibacterial Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

Impact on Demand
Impact on Healthcare
Epidemiology

5. Global Antibacterial Drugs Market, By Drug Class, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
B-lactams
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Quinolones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
Macrolides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Tetracyclines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
Aminoglycosides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Sulfonamides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
Phenicols
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)

6. Global Antibacterial Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)

7. Global Antibacterial Drugs Market, By Region, 2017 - 2030 (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030(%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2030
- Regional Trends
North America
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 - 2030 (US$ Mn)
South Africa
Central Africa
North Africa